

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

1. (currently amended) ~~Use of a substance for synthesising a drug for the treatment of patients who suffer from~~ A method for inhibiting maturation of dendritic cells for the treatment of a pulmonary disease which is directly or indirectly associated to idiopathic pulmonary disease, hypersensitive pneumonia or diffused panbronchillitis, ~~wherein said substance is~~ comprising administering to a patient a peptide or a polypeptide ~~containing~~ comprising the following amino acid sequence:

Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID NO. 4).

2. (currently amended) ~~Use~~ The method according to claim 1, wherein said peptide or a polypeptide further ~~containing~~ comprises at least one of the following amino acid sequence:

His-Ser-Asp (SEQ ID number 14); Phe-Thr-Asp (SEQ ID NO. 13).


3. (currently amended) ~~Use~~ The method according to claim 1, wherein said peptide or a polypeptide having following amino acid sequence:

(A)_n-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-(B)_m

wherein A, B is (A)_n and (B)_m independently are primary amino acid sequences comprising any sequence of natural occurring amino acid; acids; n has a value from 0 to 25 and n is the number of amino acid residues in said primary amino acid sequence

(A)_n; and m has a value from 0 to 25 and m is the number of amino acid residues in said primary amino acid sequence (B)_m. ~~A and B are independent of each other; and n, m-replacing values from 0-25; n and m are independent of each other.~~

4. (currently amended) Use The method according to claim 3, wherein if $n > 2$, said primary amino acid sequence (A)_n further comprises a primary amino acid sequence (A)_n has following sequence if $n > 2$:



wherein (X)_o and (Y)_p independently are primary amino acid sequences comprising X, Y is any sequence of natural occurring amino acid, acids; o has a value from 0 to 11 and o is the number of amino acid residues in said primary amino acid sequence (X)_o; and p has a value from 0 to 11 and p is the number of amino acid residues in said primary amino acid sequence (Y)_p. ~~X and Y are independently of each other; and o, p is a replacing value from 0-11, o and p are independent of each other.~~

5. (currently amended) Use The method according to claim 4, wherein if $o > 2$, said primary amino acid sequence (A)_n further comprises a primary amino acid sequence (X)_o has following sequence if $o > 2$:



wherein (X')_q and (X'')_r independently are primary amino acid sequences comprising X', X'' is any sequence of natural occurring amino acid, acids; q has a value from 0 to 4 and q is the number of amino acid residues in said primary amino acid sequence (X')_q; and r has a value from 0 to 4 and r is the number of amino acid residues in said primary amino acid sequence (X'')_r. ~~X' and X'' are independent of each other; and r, q is a replacing value from 0-4, r and q are independent of each other.~~

6. (currently amended) Use The method according to claim 3, wherein the sequence of said peptide or polypeptide ~~belongs to~~ is selected from the following group:

- (i) Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID NO. 4)
- (ii) Phe-Thr-Asp-X¹-X²-X³-X⁴-X⁵-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn (SEQ ID NO. 5);
- (iii) Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn (SEQ ID NO. 6);
- (iv) Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID NO. 7);
- (v) His-Ser-Asp-X¹-X²-Phe-Thr-Asp-X³-X⁴-X⁵-X⁶-X⁷-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID NO. 9);
- (vi) His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID NO. 10);
- (vii) His-Ser-Asp-X¹-X²-Phe-Thr-Asp-Asp-X³-X⁴-X⁵-X⁶-X⁷-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-X⁸-X⁹-X¹⁰-X¹¹-(X¹²) (SEQ ID NO. 11);
- (viii) His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn (VIP, SEQ ID NO. 1);
- (ix) His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys (PACAP-38, SEQ ID NO. 2);
- (x) His-Ser-Asp-X¹-X²-Phe-Thr-Asp-X³-X⁴-X⁵-X⁶-X⁷-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu X⁸-X⁹-X¹⁰-X¹¹-X¹²-X¹³-X¹⁴-X¹⁵-X¹⁶-X¹⁷-X¹⁸-X¹⁹-X²⁰-X²¹-X²² (SEQ ID NO. 12); and
- (xi) His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu (PACAP-27, SEQ ID NO. 3);

and

wherein X¹ - X²² is any naturally occurring amino acid.

7. (currently amended) ~~Use~~ The method according to claim 1, wherein any said peptide or polypeptide is an analogue or a derivative with the same biological function.

8. (currently amended) ~~Use~~ The method according to claim 7, wherein any said peptide or polypeptide is in a stabilised form.

9. (currently amended) ~~Use~~ The method according to claim 1, wherein said disease is idiopathic pulmonary fibrosis.

10. (currently amended) ~~Use~~ The method according to claim 1, wherein said disease is hypersensitive pneumonia.

11. (currently amended) ~~Use~~ The method according to claim 1, wherein said disease is diffused panbronchiolitis.

12. (currently amended) ~~Use~~ The method according to claim 1, wherein the therapeutically effective peptides are administered as aerosols.

13. (currently amended) ~~Use~~ The method according to claim 2, wherein said disease is idiopathic pulmonary fibrosis.

14. (currently amended) ~~Use~~ The method according to claim 2, wherein said disease is hypersensitive pneumonia.

15. (currently amended) ~~Use~~ The method according to claim 2, wherein the therapeutically effective peptides are administered as aerosols.

16. (currently amended) ~~Use~~ The method according to claim 3, wherein any said peptide or polypeptide is an analogue or a derivative with the same biological function.

17. (currently amended) ~~Use~~ The method according to claim 3, wherein said disease is diffused panbronchiolitis.

18. (currently amended) ~~Use~~ The method according to claim 3, wherein the therapeutically effective peptides are administered as aerosols.